Adamas Pharma (ADMS) Announces FDA Approval for Second Indication for GOCOVRI as Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

Go back to Adamas Pharma (ADMS) Announces FDA Approval for Second Indication for GOCOVRI as Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes

Adamas Pharma (ADMS) to Resume Trading at 2:35 p.m.

February 1, 2021 2:30 PM EST

Adamas Pharma (NASDAQ: ADMS) to Resume Trading at 2:35 p.m.

... More

Adamas Pharma (ADMS) halted, news pending

February 1, 2021 1:02 PM EST

Adamas Pharma (NASDAQ: ADMS) halted, news pending

... More